LifeCycle Pharma To Present at BioEquity Europe 2007 Biotechnology Conference


Investor Service Announcement no. 2/2007                                        

	Hørsholm, Denmark, 16 May 2007                                                 


              LifeCycle Pharma To Present at BioEquity Europe 2007              
                            Biotechnology Conference                            

Summary: LifeCycle Pharma to Present at BioEquity Europe 2007 Biotechnology     
Conference                                                                      

LifeCycle Pharma A/S (OMX:LCP) today announced that its President and CEO, Dr.  
Flemming Ornskov, will be presenting a company update at the BioEquity Europe   
2007 Biotechnology Conference on 22 May 2007 at 10:25 local time in room        
Megalithic 1. The two-day conference is being held at the Radisson SAS Hotel in 
Glasgow, Scotland. The conference will feature presentations from select        
European companies.                                                             

For further information please contact:                                         
LifeCycle Pharma A/S                                                            
Michael Wolff Jensen                                                            
Executive Vice President and CFO                                                
Tel. +45 40 74 62 44                                                            

                                  ---oo0oo---                                   

About LifeCycle Pharma A/S:                                                     
LifeCycle Pharma, headquartered in Hørsholm, Denmark, is an emerging            
pharmaceutical company with a broad and late stage product pipeline in          
therapeutic areas of cholesterol management, hypertension, organ transplant and 
autoimmune diseases. LifeCycle Pharma's product candidates are proprietary and  
designed to improve the quality of existing drugs by enhancing the release and  
absorption of drugs in the human body. LifeCycle Pharma's proprietary technology
platform, MeltDose® technology, offers lower dosing, reduced side effects and   
improved safety and patient compliance, as well as reduced product development  
time and development costs. LifeCycle Pharma is listed on the OMX Nordic        
Exchange under the trading symbol (LCP). Please visit www.lcpharma.com for      
further information about LifeCycle Pharma A/S.

Attachments

20070516-lifecycle pharma to present at bioequity.pdf